About Xencor
Xencor is a company based in Monrovia (United States) founded in 1997.. Xencor has raised $7.6 million across 3 funding rounds. The company has 250 employees as of December 31, 2024. Xencor offers products and services including XmAb Platform, Bispecific Antibodies, and Cytotoxic Fc Domains. Xencor operates in a competitive market with competitors including Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
- Headquarter Monrovia, United States
- Employees 250 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xencor, Inc.
-
Annual Revenue
$110.49 M-36.72as on Dec 31, 2024
-
Net Profit
$-232.62 M-74.73as on Dec 31, 2024
-
EBITDA
$-166.3 M-37.59as on Dec 31, 2024
-
Total Equity Funding
$7.6 M (USD)
in 3 rounds
-
Latest Funding Round
$7.6 M (USD), Series A
Jun 28, 2013
-
Investors
-
Employee Count
250
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Xencor
Xencor is a publicly listed company on the NASDAQ with ticker symbol XNCR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Xencor
Xencor offers a comprehensive portfolio of products and services, including XmAb Platform, Bispecific Antibodies, and Cytotoxic Fc Domains. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineering platform for developing antibody therapeutics
Targeted treatments for cancer and immune disorders
Domains enhancing antibody drug efficacy in diseases
Unlock access to complete
Unlock access to complete
Leadership Team
45 people
Software Development Team
16 people
Senior Team
14 people
Product Management Team
9 people
Principal Team
7 people
Operations Team
7 people
Finance and Accounting
6 people
Associate Team
6 people
Unlock access to complete
Funding Insights of Xencor
Xencor has successfully raised a total of $7.6M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $7.6 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $7.6M
-
First Round
First Round
(10 Apr 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2013 | Amount | Series A - Xencor | Valuation |
investors |
|
| Dec, 2010 | Amount | Debt – Conventional - Xencor | Valuation |
investors |
|
| Apr, 2009 | Amount | Debt – Conventional - Xencor | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Xencor
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Xencor
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xencor Comparisons
Competitors of Xencor
Xencor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xencor
Frequently Asked Questions about Xencor
When was Xencor founded?
Xencor was founded in 1997 and raised its 1st funding round 12 years after it was founded.
Where is Xencor located?
Xencor is headquartered in Monrovia, United States. It is registered at Monrovia, California, United States.
Who is the current CEO of Xencor?
Bassil I Dahiyat is the current CEO of Xencor.
Is Xencor a funded company?
Xencor is a funded company, having raised a total of $7.6M across 3 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $6M, raised on Apr 10, 2009.
How many employees does Xencor have?
As of Dec 31, 2024, the latest employee count at Xencor is 250.
What is the annual revenue of Xencor?
Annual revenue of Xencor is $110.49M as on Dec 31, 2024.
What does Xencor do?
Xencor is developing superior monoclonal antibody therapeutics optimized to treat autoimmune disorders, asthma and allergic diseases, and cancer. Its antibody engineering platform precisely alters the Fc domain (the stem of the antibody structure) to significantly enhance natural functions and performance. Its product pipeline includes XmAb5871, a monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target FcγRIIb, a receptor that inhibits B cell function current in Phase 2 for the treatment of rheumatoid arthritis and lupus XmAb7195 for AsthmaAllergy. Also, have preclinical stage antibodies for the treatment of different cancers.
Who are the top competitors of Xencor?
Xencor's top competitors include Merck, Moderna and Roivant Sciences.
What products or services does Xencor offer?
Xencor offers XmAb Platform, Bispecific Antibodies, and Cytotoxic Fc Domains.
Is Xencor publicly traded?
Yes, Xencor is publicly traded on NASDAQ under the ticker symbol XNCR.
What is Xencor's ticker symbol?
The ticker symbol of Xencor is XNCR on NASDAQ.